Results 141 to 150 of about 5,090 (179)
Current Research of the Pharmaceutical Industry [PDF]
, 2012 Gnant, Michael +2 more
core +1 more source
Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. [PDF]
J Immunother Cancer, 2021 europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Talimogene Laherparepvec (T-VEC)
2021Talimogene laherparepvec (T-VEC, IMLYGIC®) is the first approved oncolytic virotherapy for the treatment of patients with advanced melanoma. As the drug is administered intratumorally, it is mainly suitable for the treatment of (sub)cutaneous lesions.
Zdzienicki, Marcin +3 more
openaire +1 more source
Retreatment with Talimogene Laherparepvec for Advanced Melanoma
Immunotherapy, 2020Aim: Talimogene laherparepvec (T-VEC) is a genetically modified oncolytic herpesvirus approved for the treatment of unresectable, locoregionally advanced and recurrent melanoma. There is little relevant literature in the context of retreatment with T-VEC. Materials & methods: We reviewed four patients aged 71-87 years old with stage IIIB-IV melanoma at
Janice Hu +4 more
openaire +2 more sources
Implementing a Program of Talimogene laherparepvec
Annals of Surgical Oncology, 2018Oncolytic viruses are genetically engineered or naturally occurring viruses that selectively replicate in cancer cells without harming normal cells. Talimogene laherparepvec (Imlygic®), the first oncolytic viral therapy approved for treatment of cancer, was approved for treatment of locally advanced melanoma in October 2015.As a biologic product, use ...
Frances Collichio +6 more
openaire +2 more sources
Talimogene laherparepvec (T-VEC) as cancer immunotherapy
Drugs of Today, 2015Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer ...
F J, Kohlhapp, A, Zloza, H L, Kaufman
openaire +2 more sources
Talimogene Laherparepvec: First Global Approval
Drugs, 2015Talimogene laherparepvec (Imlygic™) is an oncolytic viral therapy that is being developed by BioVex (a subsidiary of Amgen) for the intralesional treatment of various cancers, including malignant melanoma. Talimogene laherparepvec is a genetically modified, live, attenuated, herpes simplex virus type 1 that is designed to promote an antitumour response
openaire +2 more sources